FSHD is characterized by the misexpression of DUX4 in skeletal muscle. However, DUX4 is lowly expressed in patient samples and analysis of the consequences of DUX4 expression has largely relied on artificial overexpression. To better understand the native expression profile of DUX4 and its targets, we performed pooled RNA-seq differentiation time-course in FSHD2 patient-derived primary myoblasts and identified early-and late-induced sets of FSHDassociated genes. Using single-cell and single-nucleus RNA-seq on FSHD2 myoblasts and myotubes respectively, we captured DUX4 expression in single-nuclei and found that only some DUX4 targets are coexpressed. We identified two populations of FSHD myotube nuclei with distinct transcriptional profiles. One population is highly enriched with DUX4 and FSHD related genes, including the DUX4 paralog DUXA (FSHD-Hi). The other population has no expression of DUX4 and expresses low amounts of FSHD related genes (FSHD-Lo), but is marked by the expression of CYTL1 and CHI3L1. FSHD-Hi myotube nuclei upregulated a set of transcription factors (TFs) that may form a self-sustaining network of gene dysregulation, which perpetuates this disease after DUX4 is no longer expressed.
Introduction
Fascioscapulohumeral muscular dystrophy (FSHD) is one of the most common inherited muscular dystrophies and is characterized by progressive wasting of facial, shoulder and upper arm musculature [1] . The most common form of FSHD, FSHD1 (>95% of cases), is linked to the mono-allelic contraction of the D4Z4 macrosatellite repeat array on chromosome 4q from 11-100 units to 1-10 units, with each 3.3 kb repeat containing the open reading frame for the doublehomeobox transcription factor DUX4 [2] [3] [4] . In contrast, FSHD2 (<5% of FSHD cases) has no contraction of the chromosome 4q repeat array. More than 80% of FSHD2 cases are characterized by recurring mutations in the chromatin modifier SMCHD1 (Structural Maintenance of Chromosomes flexible Hinge Domain-containing protein 1) on chromosome 18 [5] . SMCHD1 is important for maintenance of DNA methylation and epigenetic silencing of multiple genomic loci, including the D4Z4 repeat array [5] . Studies have also found that SMCHD1 mutations can act as disease modifiers in severe cases of FSHD1 [6, 7] .
FSHD is associated with the expression of the full-length DUX4 transcript (DUX4fl) which is stabilized by a specific single-nucleotide polymorphism in the chromosomal region distal to the last D4Z4 repeat by creating a canonical polyadenylation signal [8] [9] [10] . DUX4fl encodes a transcriptional activator with a double-homeobox domain that binds to a specific sequence motif upstream of its target genes in the genome [3, 4] . Normally, DUX4 is briefly expressed in 4-cell human embryos when it activates genes for zygote genome activation (ZGA) [11] [12] [13] . In muscle cells, overexpression of DUX4fl causes differentiation defects and cytotoxicity in human and mouse myoblasts [14, 15] . However, the endogenous DUX4fl is expressed at extremely low levels in FSHD and DUX4 protein is only detected in 0.001% and 0.005% of patient myoblasts and myotubes, respectively, in vitro [16] . The relationship of DUX4-positive and -negative cells and whether DUX4-negative patient cells contribute to the disease is unclear. The regulation of DUX4 expression is controlled by multiple epigenetic processes. D4Z4 repeats are normally heterochromatic with DNA hypermethylation and histone H3 lysine 9 trimethylation (H3K9me3), which are lost in FSHD1 and FSHD2 [17, 18] . The depletion of SMCHD1, which binds to D4Z4 repeats in an H3K9me3-dependent fashion [2] , results in DUX4fl upregulation and mutations throughout the gene correlate with CpG hypomethylation in D4Z4 repeats [19] .
Here we focused on the SMCHD1-mutated FSHD2 subtype in order to characterize the heterogeneity of DUX4 and FSHD-induced target gene expression at the single-cell level using in vitro differentiation of primary FSHD2 patient-derived myoblasts into myotubes. Although FSHD2 represents a minor population of FSHD cases, patient cells exhibit comparable clinical and gene expression phenotype as FSHD1 [20] . We used two FSHD2 patient samples with defined genetic mutations of SMCHD1 and significant DNA hypomethylation of D4Z4. Using pooled RNA-seq, we profiled gene expression patterns during a differentiation time-course and identified candidate disease-related key genes (i.e. FSHD-induced genes) that are upregulated specifically in FSHD cells by comparing expression profiles between FSHD2 and control. We found that about 40% of differentially expressed genes are known FSHD-associated genes while the others may be potential new candidates involved in the progression of the disease. We then used single-cell RNA-seq in myoblasts and single-nucleus RNA-seq [21] in 3-day postdifferentiation myotubes to characterize the expression patterns of DUX4 and other FSHDinduced genes. We sucessfully detected the first set of single nuclei with DUX4 expression (DUX4-detected) from FSHD myotubes and found that they do not express all the FSHDinduced genes whereas a much larger set of FSHD myotube nuclei express FSHD-induced genes. Using pseudotime analysis on the single-cell/single-nucleus data, we also found two interesting bifurcation time points that (1) separate FSHD2 myotube nuclei from control myotube nuclei and (2) distinguish FSHD myotube nuclei that have low expression of FSHD-induced genes (termed "FSHD-Lo") from the nuclei with high expression of FSHD-induced genes (termed "FSHD-Hi") nuclei. FSHD-Hi nuclei, either with or without DUX4 expression, show the highest enrichment of FSHD differentialy expressed genes observed in the population-based analysis. We found that DUX4 and its paralogs, DUXA and DUXB, are expressed in "FSHD-Hi" and "FSHD-Lo" nuclei respectively and have distinct coexpression patterns with other FSHDinduced genes. These two populations of FSHD myotube nuclei may enter distinct biological programs driven by differential expression of specific sets of transcrition factors downstream of DUX4.
Results

Upregulation of FSHD-induced genes during FSHD2 myotube differentiation
Previous studies indicated that DUX4 is upregulated during FSHD patient myoblast differentiation [22] . In order to understand the temporal expression differences between FSHD2 patient-derived and control myoblasts, we differentiated these in vitro to measure the dynamics of gene expression in a 6-day time-course using conventional pooled RNA sequencing (RNAseq) ( Figure 1A , S1) (Methods). We used two independent primary control myoblast samples, Control-1 and Control-2, and two independent primary FSHD2 myoblast samples, FSHD2-1 and FSHD2-2, which have known SMCHD1 mutations. In addition, we compared our time-course to the differentiation of the immortalized human myoblast cell line KD3 [23] which was used previously to study the fate heterogeneity during myotube differentiation by single-nucleus RNA-seq [21] . After sequencing two biological replicate RNA samples for each of the five cell populations every day for six days, we filtered out lowly expressed genes across all 60 samples and performed principal component analysis (PCA) with 10,767 genes ( Figure 1B) . We observed that the days of differentiation aligned to each other across cell lines following a clear trajectory of myogenesis (PC1, 34.3% variance in expression). FSHD2 and control clearly separated from KD3 by the second principal component (PC2, 19.1% variance in expression) which may be due to the immortalization of KD3 and/or the different muscles from which they were derived (control and FSHD2-2 myoblast cells were from quadriceps, and FSHD2-1 myoblast cells were from tibia; KD3 from trunk muscle) ( Figure S2 ). We also found that the two FSHD2 cell lines had similar variance in expression to the two control cell lines at the early differentiation timepoints but separated distinctly for days 3 to 5 in two principal components with known genes upregulated in FSHD driving the variance (PC4, 6.6% variance in expression; PC7, 3.6% variance in expression) ( Figure 1B , Table S1 ). Thus, FSHD2 patient-derived myotubes can be distinguished from control and KD3 cells by day 3 of differentiation when profiling transcriptomes at the population level.
In order to comprehensively characterize the expression of DUX4 and its associated upregulated genes during myogenesis, we examined differentially expressed genes (log2|FC|>3) by comparing between FSHD2 and control at each day of the time-course (Methods). We identified 103 differentially expressed genes (68 upregulated, 35 downregulated) in FSHD2 across the time-course ( Figure 1C , Table S2 ). Of the 68 upregulated genes, we call 36 as confirmed DUX4 targets since they have been shown to be overexpressed in DUX4-positive myotubes [22] or in FSHD muscle biopsies, and/or they have DUX4 binding sites confirmed by ChIP-seq [20] ( Figure 1C red astericks, S3). We define 59 "FSHD-induced genes" as the set of known DUX4 target genes, genes upregulated in previous FSHD studies, and novel genes upregulated across this FSHD2 differentiation time-course ( Figure 1C red box) . Previously published FSHD-induced genes [20, 22, 24] were upregulated in waves starting at day 2, such as TRIM43, MBD3L2, MBD3L3, KHDC1L and LEUTX, followed by day 3, such as PRAMEF1, PRAMEF2, PRAMEF12, ZSCAN4 and MBD3L5, and day 4, such as CCNA1, KDM4E, PRAMEF17, PRAMEF6 [20] (Figure 1C, S3 ). After being significantly upregulated, most FSHD-induced genes remained upregulated through the end of the time-course ( Figure 1C ). As DUX4 protein was shown to be transiently expressed [22] , the continued up-regulation of these genes could be due to a self-supporting network of gene regulation initially induced by DUX4 then possibly mediated by transcription factors and chromatin remodelers, such as ZSCAN4 and MBD3L2. Interetingly, DUXA and DUXB, which are paralogs of DUX4 [25] , were also stably activated starting at days 3 and 4, respectively, in FSHD2 samples suggesting their potential contribution in FSHD-related pathways.
In order to identify temporal patterns of expression, we used maSigPro [26] to cluster the differentially expressed genes into four clusters with genes upregulated in FSHD2 separating into early-(clusters 1) and late-induced expression patterns (cluster 4) (Figure 2A , 2B, 2D) (Methods). Importantly, known DUX4-associated upregulated genes [20] represent over 70% of the genes induced in later stage, indicating that other genes within the same clusters could be novel candidate target genes for DUX4 in FSHD2. Genes induced at the later stage (cluster 4) were highly enriched in GO terms for negative regulation of cell differentiation (p=1x10 -9.76 ) and methylation-dependent chromatin silencing (p=1x10 -5.56 ) ( Figure 2D , 2E, Table S3 ) while genes induced at the beginning of differentiation (cluster 1) were enriched in GO terms for leukocyte migration (p=1x10 -5.24 ), humoral immune response (p=1x10 -2.96 ), response to oxidative stress (p=1x10 -2.67 ) and chromatin organization (p=1x10 -1.96 ) ( Figure 2B , 2C, Table S3 ). The other two clusters represent genes upregulated in both FSHD2 and control differentiation (cluster 2) or only in Control-2 (cluster 3) ( Figure S4 , Table S3 ). In summary, we found a set of genes significantly upregulated in differentiating FSHD2 myotubes with distinct early and late dynamics with most of the characteristic FSHD-induced genes activated by day 3.
Detection of nuclei with DUX4 expression from FSHD2 myotubes using single-nucleus RNA-seq
Although we failed to detect DUX4 in our pooled RNA-seq, the upregulation of FSHDinduced genes was nevertheless observed during myotube differentiation specifically in FSHD2 samples. We wondered whether the expression of FSHD-induced genes is seen in every cell and whether the expression of DUX4 and DUX4-target genes were indeed present only in a subset of cells. We therefore performed single-cell RNA-seq on undifferentiated myoblasts and singlenucleus RNA-seq on myotubes using the Fluidigm C1 platform [21] at day 3 of differentiation using control and FSHD2 primary cells ( Figure S5A ). Day 3 was chosen as it was the first day of robust FSHD-induced gene expression in the differentiation time-course thereby allowing us to observe early transcriptional changes. Given the unique profile of Control-2 ( Figure S4D ), we used Control-1 for single-cell/single-nucleus experiments. Additionally, we selected FSHD2-2 based on the higher expression level of FSHD-induced genes compared to FSHD2-1 during differentiation (Figure 2A, D) . We also compared these results to our previously published data on single-cell/single-nucleus RNA-seq in immortalized KD3 cells [21] . As quality control that our single cell data matched our pooled time-course, we first pooled reads from all single cells/single nuclei for each cell type and performed incremental PCA with the pooled timecourse RNA-seq samples ( Figure S5B, S5C ). As expected, the pooled single-cell myoblasts clustered with day 0 samples in both control and FSHD2. For the pooled myotube single nuclei, FSHD2 replicate 1 (FSHD2 R1) aligned with day 3 of the FSHD2 time-course, but FSHD2 replicate 2 (FSHD2 R2) located between control and FSHD2 day 3 in the time-course ( Figure  S5C ). This suggests variable differentiation efficiencies for the two replicates, which could be caused by subtle differences in seeding density.
Importantly, we found that 3 out of 79 (3.8%) nuclei in FSHD2 R1 showed high expression of DUX4 (11.24 TPM, 34.15 TPM and 68.49 TPM) while we detected no DUX4-detected nuclei in FSHD2 R2, revealing the high level of heterogeneity in the FSHD2 cell population with DUX4 only expressed in a small fraction of nuclei. We then analyzed the global profiles of the single-cell transcriptomes using PCA analysis and found that all 3 DUX4-detected nuclei as well as other FSHD2 R1 nuclei clearly separated from FSHD2 R2 and control myotube nuclei ( Figure  3A) . We analyzed 59 FSHD-induced genes specifically upregulated at day 3 or later during our pooled time-course of FSHD2 differentiation ( Figure 1C ) and observed that these genes showed significant enrichment in FSHD2 R1 myotube nuclei compared with control myotube nuclei (p<2.2x10 -16 ). Nuclei with the highest enrichment clustered with the 3 DUX4-detected nuclei, and thus we labeled this group of nuclei "FSHD-induced genes high" ("FSHD-Hi") ( Figure 3B , S6A). The FSHD2 R2 myotube nuclei also showed significantly higher enrichment of FSHDinduced genes than control myotube nuclei (p<2.2x10 -16 ) but had fewer FSHD-induced genes expressed than the "FSHD-Hi" group, and therefore this group of nuclei was labeled "FSHDinduced genes low" ("FSHD-Lo") ( Figure 3B , S6A). However, genes downregulated during FSHD2 myogenesis were comparable across all types of cells/nuclei but with significantly lower detection in the "FSHD-Hi" nuclei ( Figure S6A, S6B ). In summary, we detected three different patient myotube nuclei populations: (1) a set of 3 nuclei that express endogenous DUX4 (DUX4-detected) and FSHD-induced genes ("FSHD-Hi"); (2) a larger set of 76 nuclei that express FSHD-induced genes but no detectable DUX4 ("FSHD-Hi"); and (3) 60 nuclei that are clearly different from control nuclei but nevertheless with no DUX4 and significantly lower FSHDinduced gene expression ("FSHD-Lo").
To assess whether these groups of nuclei have distinct expression of FSHD-induced genes, we determined the coexpression patterns between a subset of FSHD-induced genes which had variable expression in the single cells and nuclei (excluding 7 genes MMP9, TREM1, HNRNPCL3, PRAMEF17, PRAMEF2, PRAMEF20 and RBP7 that were not detected as well as NBPF26 that was expressed in all single cells and nuclei). We found that all myoblast cells and control or KD3 myotube nuclei typically express rarely more than 2 FSHD-induced genes ( Figure 3C ), whereas "FSHD-Lo" nuclei coexpress between 1 to 5 and at most 7 of the FSHDinduced genes. However, all "FSHD-Hi" nuclei express at least 6 of these genes with most coexpressing at 10 and up to 18 genes ( Figure 3C ). To determine expression profiles of DUX4-detected nuclei, we examined genes coexpressed with DUX4. We found that DUX4 was coexpressed with 20 FSHD-induced genes including two transcription factors, LEUTX and ZSCAN4, which have been reported as DUX4 targets in FSHD ( Figure S7 ) [20, 22] . DUX4 and ZSCAN4 were expressed in all three DUX4-detected nuclei while DUX4 and LEUTX were only simultaneously expressed in one DUX4-detected nuclei. FSHD-induced genes coexpressed in all three DUX4-detected nuclei include KHDC1L, SLC34A2, PRAMEF9, RFPL4B and ZSCAN4, while genes like TRIM49, MBD3L2, MBD3L3 and MBD3L5 are coexpressed with DUX4 in two of the DUX4-detected nuclei. Additionally, the nucleus with DUX4, LEUTX and ZSCAN4 also expressed KDM4E, TRIM43, TRIM43B, MBD3L3, MBD3L5, and RFPL2. Taken together, the genes expressed in the DUX4-detected nuclei may represent early targets of DUX4 which initiate a pathogenic gene regulatory network ( Figure S7 ). Indeed, 18 of the 20 FSHD-induced genes expressed in at least one DUX4-detected nucleus are bound by DUX4 or in a gene cluster which is bound by DUX4 (i.e. MBD3Ls) [20, 22] .
Interestingly, we observed the expression of DUX4 paralogs expressed in FSHD2 myotube nuclei. DUXA was expressed exclusively in the "FSHD-Hi" nuclei population while DUXB was only expressed in "FSHD-Lo" nuclei. In addition, CHI3L1 was significantly higher in "FSHD-Lo" nuclei compared with "FSHD-Hi" myotube nuclei, while CYTL1 was expressed exclusively in "FSHD-Lo" myotube nuclei ( Figure 4B , 4C, S8) and in FSHD2 myoblasts ( Figure  2A , 4C). To identify correlated gene regulation between the populations, we used the distinct expression profiles of DUX4, DUXA, DUXB, CHI3L1 and CYTL1 to mark the three FSHD2 myotube nuclei populations mentioned above and to observe their coexpression patterns with FSHD-induced genes ( Figure 3D ). We found that 19 FSHD-induced genes were coexpressed in both "FSHD-Hi" and "FSHD-Lo" populations, including reported DUX4 targets LEUTX, ZSCAN4, MBD3L2, TRIM43, KHDC1L and CCNA1 [4, 20, 24] , indicating that they may perform as a core set of responsive and interactive genes during FSHD progression ( Figure 3D ). We observed that 15 FSHD-induced genes were coexpressed only in the "FSHD-Hi" population, such as KDM4E, PRAMEF1, PRAMEF11, PRAMEF12 and SLC34A2, and 9 genes were exclusively coexpressed in the "FSHD-Lo" population. As expected, CYTL1 and CHI3L1 were more frequently coexpressed in "FSHD-Lo" compared with other nuclei ( Figure 3D ). "FSHDHi" and "FSHD-Lo" have distinct coexpression patterns that indicate different cell states. Within the "FSHD-Hi" nuclei a large number of the FSHD-induced genes are coexpressed with transcription factors, such as LEUTX and DUXA, but not DUX4. Taken together, two identified patient myotube nuclei populations, "FSHD-Hi" with a small set of DUX4-detected nuclei and "FSHD-Lo", exhibit distinct co-expression patterns of FSHD-induced genes including DUX4-target TF genes.
Heterogeneity of FSHD-induced gene expression in FSHD2 myotube nuclei
In order to further characterize the heterogeneous expression of DUX4 and DUX4-associated FSHD-induced genes, we performed tSNE analysis on single-cell and single-nucleus RNA-seq samples. Similar to the PCA in Figure 3B , "FSHD-Hi" nuclei clearly separated from "FSHD-Lo" and control myotube nuclei ( Figure 4A ). Furthermore, we found that DUX4 and FSHD-induced genes were often not expressed in the same nuclei ( Figure 4A , 4B, S8-S11). To determine whether FSHD-induced gene expression was transient at the single nucleus level or persisted as expected from the pooled time-course ( Figure 1C) , we examined the expression of sets of genes significantly upregulated starting at days 2, 3 and 4 in our single-cell/single-nucleus data ( Figure 4B ). We found that genes significantly upregulated starting on days 2 and 3 in our pooled time course analysis were expressed in a higher proportion of nuclei and with higher expression levels in "FSHD-Hi" nuclei compared with other nuclei. We also observed this when looking at the expression of all 59 FSHD-induced genes in single cells and nuclei ( Figure 4C ). Interestingly, most of the genes with significant upregulation starting on days 0, 4 or 5 of differentiation were sparsely expressed in "FSHD-Hi" nuclei, and some had higher enrichment in "FSHD-Lo" nuclei ( Figure 4C ). For example, CHI3L1, significantly upregulated starting on day 4, was highly enriched in "FSHD-Lo" nuclei. We also observed that CYTL1, which was significantly more highly expressed in FSHD starting at day 0, was exclusively expressed in "FSHD-Lo" nuclei. To sum up, in "FSHD-Hi" we see that the genes which are upregulated beginning at day 2 are expressed along with those from day 3 in our day 3 myotubes, implying persistence of upregulation as seen in the pooled time-course. However, the "FSHD-Lo" myotubes show random expression of genes found to be upregulated very early or late in the pooled time-course, indicating the disease-related responses are more heterogeneous in "FSHDLo" than "FSHD-Hi" nuclei.
To substantiate the relationship between DUX4-detected nuclei and other nuclei from the same or different myotubes, we performed RNA FISH on DUX4 and two representative FSHDinduced genes, LEUTX and SLC34A2, in 3-day differentiated FSHD2-2 myotubes. Probes were designed to hybridize to the two regions unique to the DUX4fl transcript to ensure the specificity. We observed that ~7% of myotubes have at least 1 DUX4-detected nucleus, and that DUX4-positive myotubes contain on average 2 DUX4-detected nuclei (among on average 15 nuclei per myotube). While the DUX4 transcript is often detectable only in the nucleus, LEUTX and SLC34A2 mRNA transcripts are abundantly present in the cytoplasm as well as in multiple nuclei suggesting that the DUX4 protein activates their transcription in multiple nuclei of a single myotube ( Figure 4D ). Furthermore, the DUX4 transcript signal is very low or undetectable in some myotubes while LEUTX and SLC34A2 transcripts are detected ( Figure 4D , S12). These results strongly suggest that FSHD-induced genes can persist even after DUX4 transcription has ceased, which explains the long-standing observation in previous studies that FSHD-induced gene expression is easier to detect in patient muscle cells than the DUX4 transcript itself.
"FSHD-Hi" nuclei form a distinct branch on the pseudotime of single-cell and singlenucleus differentiation
We performed a pseudotime analysis using Monocle [27] in order to understand whether the cells expressing FSHD-induced genes followed a distinct developmental trajectory (Methods). We reordered 349 single-cells/single-nuclei based on pseudotime ( Figure S5A ), which recapitulated the differentiation trajectory from myoblast to myotube and identified additional subpopulations in myotube nuclei compared with myoblast cells ( Figure 5A ). Interestingly, the "FSHD-Hi" nuclei population with three DUX4-detected myotube nuclei formed a homogenous cluster (branch 7, with only one KD3 myotube nucleus) at one end of the pseudotime and showed upregulation of the FSHD-induced genes that we had identified in our pooled RNA-seq differentiation time-course ( Figure 5A ). Nuclei from the "FSHD-Lo" population mixed with many control myotube nuclei (branches 2 and 3), while some located on the same branch as myoblast cells (branch 1) in terms of pseudotemporal position ( Figure 5A ) indicating that the heterogeneity in this population might be in part caused by a less advanced differentiation status. We further characterized the expression of genes induced late in FSHD2 differentiation (cluster 4, Figure 2D ) in single cells/nuclei ( Figure 5C ). Late-induced genes were more highly enriched in FSHD2 myotube nuclei compared with others and were almost entirely not expressed in myoblast cells ( Figure S13A) . Genes induced at the beginning of differentiation (cluster 1, Figure 2B ), however, were expressed in both myoblast cells and myotube nuclei (Figure 5B , S13B). These results further confirm the importance of later-stage induced genes in distinugishing between control and disease phenotypes. As mentioned above, genes induced late in FSHD2 differentiation (cluster 4, Figure 2D ) were detected in the FSHD2 single myotube nuclei include known DUX4 targets such as ZSCAN4, MBD3L2, KHDC1L, LEUTX [4, 20, 24] , as well as DUX4 paralogs DUXA and DUXB. We found these DUX4 targets, including DUXA but not DUXB, were also coexpressed in the "FSHD-Hi" nuclei without DUX4 detected (branch 7) ( Figure 3D , S14) strongly suggesting that these nuclei are responding to the presense of the DUX4 protein in the same myotubes even though DUX4 is not being transcribed in the same nuclei.
Although DUX4 and FSHD-induced genes are thought to inhibit myogenesis in FSHD2 [28] , the pseudotemporal positions of cells and nuclei suggest that myotube maturation may also affect the expression of DUX4 and its targets. We found that markers of myotubes, such as TTN and MYBPH, have higher expression in branches 5, 6 and 7 compared with the ones in branches 2 and 3 ( Figure 5D , S15A) with highest expression in branch 7. However, ACTA1 was highly expressed in branches 2, 3 and 7 but not in 5 and 6, while CKM was highly expressed in branches 5 and 7 but not others ( Figure 5D , S15A). Interestingly, we found that desmin was also significantly more highly expressed in branch 7 ("FSHD-Hi" nuclei) than other branches ( Figure  5D , S15B). By comparing between branches, we found that desmin, MYOG and ACTA1 were significanly upregulated in branch 7 ("FSHD-Hi") ( Figure 6A ) while they showed similar expression levels between branches 2 and 3 ("FSHD-Lo" with some control nuclei) and branches 5 and 6 (control and KD3 nuclei). We also observed that "FSHD-Hi" myotube nuclei expressing more FSHD-induced genes had higher expression of both desmin, MYOG ( Figure 5E ) and ACTA1 ( Figure S15C ) but had similar expression levels of MYOD1 ( Figure 5F ) and CKM ( Figure S15D ) compared with other myotube nuclei. Given that the "FSHD-Hi" nuclei in branch 7 expressed more desmin than the "FSHD-Lo" nuclei in branches 2 and 3, we propose that the maturation state of the myotube is closely linked to DUX4 and FSHD-induced genes expression and that high desmin expression appears to signify the "FSHD-Hi" state of patient myocytes.
Identification of TFs as potential regulators downstream of DUX4 in FSHD2
"FSHD-Hi" myotube nuclei are highly enriched in FSHD-induced genes compared to "FSHD-Lo" or control myotube nuclei. Interestingly, more than half of the FSHD-induced genes that are coexpressed in "FSHD-Hi" are also coexpressed in the "FSHD-Lo" population, providing evidence that even at a low level "FSHD-Lo" cells are undergoing disease-specific changes ( Figure 3D ). Of the FSHD-induced genes that are coexpressed in DUX4-detected nuclei, 95% are also coexpressed in other "FSHD-Hi" nuclei, supporting the notion that DUX4 protein diffuses to and is exerting its regulatory effects in multiple nuclei within the same myotube ( Figure S7, S14) . Interestingly, however, we found that a unique subset of FSHD-induced targets are coexpressed with either DUXA, LEUTX, and/or ZSCAN4 only in "FSHD-Hi" nuclei without DUX4 detected, indicating the varied transcriptional responses in different nuclei ( Figure S14 ). Downstream TFs of DUX4 may interact with these FSHD-induced genes and play important roles in mediating the pathogenic program.
To further elucidate the possible regulators of this program, we performed differential expression analysis between nuclei in branch 7 ("FSHD-Hi") and other branches. We identified 2,061 genes significantly upregulated in branch 7 including myogenic differentiation markers and multiple FSHD-induced genes ( Figure 6A, 6B) . MYOD1, MYOG and ACTA1 were more highly expressed in branch 7 "FSHD-Hi" nuclei while a cell cycle gene, CDK1, was downregulated ( Figure 5D, 6A) . The myoblast marker MYF5 was one of the top upregulated TFs in the other branches compared to branch 7 ( Figure 6A ). Additionally 50 TFs were upregulated in branch 7 which did not include DUX4 but did include previously reported TFs activated in FSHD, such as LEUTX, ZSCAN4, PITX1, and DUX4 [4, 20, 24, 29] . We observed several TFs, such as DUXA, GATA3, TEAD4, LBX1, TBX1, KLF2, HOXA1, HOXA4, FOXH1 and NKX3-2, associated with embryonic organ development and muscle organ development upregulated in most of the nuclei in branch 7 but in less than 25% of cells or nuclei in other branches ( Figure  6B , 6C).These results indicate the activation of a distinct gene regulatory network in branch 7 "FSHD-Hi" nuclei.
To gain insight into a possible network of gene regulation downstream of DUX4 activation, we analyzed the coexpression patterns of these TFs in "FSHD-Hi" myotube nuclei and found similar coexpression patterns for the TFs as was found for the FSHD-induced genes ( Figure S14 ). The majority of TFs coexpressed with DUX4 in DUX4-detected nuclei were also coexpressed with DUXA in other "FSHD-Hi" nuclei, and many TFs were coexpressed only in these nuclei ( Figure 6D , S14). Twenty TFs were coexpressed with LEUTX and ZSCAN4 in both DUX4-detected and other "FSHD-Hi" nuclei, and these TFs were significantly enriched in embryonic organ development (p=1x10 -8.19 ) and chordate embryonic development (p=1x10 -5.89 ), including HOXA4, HSF1, TBX1, TBX2, TEAD4, FOXH1, IRX5, SOX8, KLF2, ARX, HES2, HOXA1, SOX6 and MZF1. HES2 is involved in the PI3K-Akt signaling pathway and is known to regulate immue cell development as well as repressing myogenesis by Notch signaling [30, 31] . SOX6 and MZF1 have been reported to regulate the FSHD region genes FRG1 and FRG2KP [32] . Another 27 TFs were only expressed in "FSHD-Hi" nuclei with no DUX4 detected and were enriched in neuron fate specification (p=1x10 -5.18 ) and muscle organ development (p=1x10 -3.01 ). Of these, ZBTB48 is known to directly bind to telomeres and to regulate their maintainance by limiting their elongation [33] . ZSCAN2, a testis-expressed gene, is also upregulated in "FSHD-Hi" nuclei, which is consistent with previous studies on DUX4-activated genes involved in germ cell and early development [4, 34] . We found that TFs which regulate muscle atrophy wasting, such as PEG3 [35] and ZBTB42 [36] , were also upregulated in "FSHD-Hi" nuclei. In addition, PITX1 and 7 others were coexpressed with LEUTX and ZSCAN4 but not DUXA or DUX4 in "FSHD-Hi" myotube nuclei. Taken together, single nucleus analysis revealed that athough a set of TFs are upregulated in "FSHD-Hi" nuclei as a whole, DUX4-detected nuclei and other "FSHD-Hi" nuclei have distinct sets of TFs coexpressed raising the possibility that the nuclear environment which permits or does not permit DUX4 expression may differentially affect the expression of other genes, invoking activation of divergent gene regulatory networks.
Discussion
Using our pooled RNA-seq time-course, we discovered two sets of FSHD-specific genes that exhibit distinct expression dynamics: 17 genes that are differentially upregulated as early as the myoblast stage ("early-induced") and a second set of 46 genes that are significantly upregulated starting at day 2 and stably activated by day 3 during FSHD2 myoblast differentiation ("late-induced"). We defined 59 genes that are stably activated by day 3 of differentiation as "FSHD-induced genes" (defined in results section). Previous studies have confirmed many genes as downstream targets of DUX4 by transcriptome and ChIP-seq analysis [20, 24] . We found that these known DUX4 targets show higher enrichment in late-induced FSHD associated genes in our study, and that other FSHD-induced genes from the same lateinduced cluster may be novel DUX4 targets. Our single-cell and single-nucleus RNA-seq analysis on control and FSHD2 myoblasts and 3-day differentiated myotubes, respectively, confirmed that FSHD2 myotube nuclei have significantly higher enrichment of FSHD-induced genes than myoblasts and control myotube nuclei. Importantly, we were able to identify DUX4 transcript-positive nuclei, which was not detected in our pooled RNA-seq. We further identified two populations of FSHD2 myotube nuclei, "FSHD-Hi" and "FSHD-Lo", based on the expression levels of FSHD-induced genes and showed that DUX4-detected nuclei belong to "FSHD-Hi". Late-induced genes showed higher expression levels in "FSHD-Hi" than in "FSHD-Lo", and a higher proportion of "FSHD-Hi" nuclei express these genes. Although both "FSHD-Hi" and "FSHD-Lo" were collected on the same day, "FSHD-Lo" shows relatively earlier differentiation status based on the time-course data and pseudotime analysis. Interestingly, however, both early-induced genes and most of the genes that are induced later on days 4 and 5 were sparsely expressed in "FSHD-Hi" nuclei, and some of were more highly enriched in "FSHD-Lo" nuclei. Therefore, our results reveal that the expression of DUX4 and its downstream targets is closely linked to the precise differentiation status of myotube and that less mature myotubes have more heterogenous responses of FSHD-induced genes.
While we only detected a small set of DUX4 transcript-positive nuclei, the proportion (3/79, 3.8%) is higher than the reported 0.05% (1/200 in myotube nuclei) [8, 10, 16] , indicating that expression levels of DUX4 could vary between individuals or be very sensitive to growth and differentiation conditions. Furthermore, we found that the expression of DUX4 in a single nucleus was higher than stated in previous population studies [8, 37] as we detected DUX4 expressed at 11.24 TPM, 34.15 TPM and 68.49 TPM in individual nuclei. Considering that DUX4 target genes were most stably upregulated at day 3 of differentiation in our time-course, our results strongly suggest that maturation status has a substantial impact on the expression of DUX4 and its target genes. Studies have previously found that DUX4 expression caused defects in muscle development and even led to cell death [14, 15] . One possible hypothesis integrating these observations is that DUX4 only activates the pathogenic FSHD gene network when expressed during a critical time window in myogenesis. Outside of this window transient DUX4 expression cannot activate these same targets possibly due to lack of necessary cofactors or epigenetic states. Pathogenesis then would have to be regulated through a downstream network of gene dysregulation. DUX4 is known to be temporally activated as a key regulator during human early embryonic development during which it activates genes involved in zygotic genome activation (ZGA) [11] . Indeed, dysregulation of DUX4 in muscle has been shown to activate germline-specific genes [4, 22, 34] . The widespread, self-supported network of gene regulation necessary for ZGA may be what proves toxic for terminally differentiated muscle. Further experiments are required to validate this proposed mechanism.
Small populations of DUX4-positive myotubes are thought to drive pathogenesis in FSHD [2] [3] [4] , which may explain the slow progress of the disorder. It is still unclear whether DUX4-negative patient muscle cells are normal or contribute to disease pathogenesis. Our highresolution single-cell and single-nucleus dataset is the first to observe the endogenous expression of DUX4 in a small number of FSHD2 myotube nuclei. We found that these nuclei cluster with a much larger set of FSHD2 nuclei expressing multiple FSHD-induced genes which we define as "FSHD-Hi". In situ RNA FISH analysis showed that DUX4 target genes are expressed in the same myotube together with a few DUX4-detected nuclei. Thus, our results clearly demonstrate that DUX4 expressed even in one nucleus is sufficient to activate DUX4 target gene expression in multiple nuclei in a single FSHD myotube. This is consistent with previous studies showing that both overexpressed recombinant and endogenous DUX4 protein diffuses to multiple nuclei within a myotube [16, 22] . We also observe a distinct population of FSHD2 nuclei (termed "FSHD-Lo") which express fewer FSHD-induced genes than "FSHD-Hi" but more than control myotube nuclei. "FSHD-Hi" and "FSHD-Lo" nuclei separated into distinct populations on the pseudotime, and both of populations clearly separated from control myotube nuclei. "FSHD-Lo" nuclei thereby represent distinct myotube population from "FSHD-Hi" nuclei. Importantly, our results indicate that even these DUX4-negative patient muscle cells exhibit disease-specific changes and suggest that they may also contribute to the disease.
While we detected FSHD-induced genes in both "FSHD-Hi" and "FSHD-Lo" myotube nuclei, many of them are coexpressed in only a subset of cells, demonstrating heterogeneous expression patterns at the single-nucleus level. Interestingly, we find distinct coexpression patterns involving DUXA, LEUTX, ZSCAN4 and other FSHD-induced genes, such as 7 PRAMEF genes and TRIM49L2 in "FSHD-Hi" myotube nuclei. Although DUXA is a DUX4 paralog [25] and has been identified as a DUX4 target gene in human patient muscle cells [20] , almost no study reports its specific functions in FSHD2 development. Similar to DUX4, DUXA is a transcription factor with two homeobox domains, and it binds to a 10bp motif similar to DUX4 [38] . Given that DUX4 and DUXA were not coexpressed in FSHD2 myotube nuclei and that DUXA was frequently coexpressed with FSHD-induced genes, we propose that, similar to DUX4, DUXA may drive an FSHD-specific pathogenic program by binding and activating a pool of downstream targets, therefore reinforcing DUX4-induced gene network in patient myotube nuclei.
Interestingly, we found novel gene markers, CYTL1 and CHI3L1, which distinguish "FSHD-Lo" myotube nuclei from "FSHD-Hi" nuclei. Although CHI3L1 (Chitinase-3-like-1) was expressed in a few "FSHD-Hi" nuclei, the proportion and expression levels were significantly higher in the "FSHD-Lo" population. CYTL1 (Cytokine-like 1) was found only in "FSHD-Lo" nuclei. CHI3L1 is located just upstream of MYOG and is more highly expressed in myotubes than myoblasts [39] . It has been shown to be expressed by exercised mytoubes and to stimulate myoblast differentiation [40] . Additionally, CHI3L1 is known to interfere with TNFα-mediated inflammation in muscle cells [41] but is implicated in pro-inflammatory response [42] and in fast developing DMD, in which inflammation exacerbates muscle dystrohpy [43] . CYTL1 has been shown to significantly prevent inflammatory arthritis [44] and has been proposed to have anti-inflammatory effects [45] . CHI3L1 and CYTL1 have also been found to be upregulated in FSHD muscle biopsies with low expression of TRIM43, LEUTX, PRAMEF2, KHDC1L, similar to our "FSHD-Lo". These tissues have mild pathology and normal MRIs with no signs of active disease, but show evidence of activation of the complement system [46] . Given the frequent coexpression of CHI3L1 and CYTL1 in "FSHD-Lo" nuclei, an antagonistic interaction between these two genes may possibly help to maintain homeostasis and further alleviate the pathological effects of FSHD-induced genes in the myotube.
Although we have detected a small set of FSHD2 myotube nuclei that express high expression of DUX4, DUX4 target genes are expressed in a larger fraction of myotube nuclei. The target gene products are also expected to diffuse through the cytoplasm of the myotubes and to alter the downstream gene expression profiles in multiple nuclei to further contribute to FSHD2-specific pathogenesis. We found a set of TFs that are specifically upregulated in "FSHDHi" myotube nuclei and that more than half of these are frequently coexpressed with LEUTX and ZSCAN4, the two known DUX4 target TFs in "FSHD-Hi" nuclei. These "FSHD-Hi"-upregulated TFs are associated with germ cell and early development, and some of them have been reported to promote muscle atrophy wasting [35, 36] . These TFs may be novel DUX4 target genes or further downstream DUX4-responsive genes which regulate a network of genes in FSHD-Hi nuclei eventually leading to the myotoxicity and dystrophy by amplifying or reinforcing the effects of the sporadic and transient expression of DUX4 through self-sustained gene dysregulation. Although we did not find significant upregulation of P53 in our "FSHD-Hi" population, the P53 upstream activator, HIC1 [47, 48] , and the P53 signaling mediator, PEG3 [35] , were upregulated in "FSHD-Hi" nuclei, and HIC1 was coexpressed with the DUX4 target PITX1, which is known to induce P53 and further promote muscle atrophy by increasing inflammation and oxidative stress [49] [50] [51] [52] . These observations challenge the assumption that endogenous DUX4 expression is autonomously toxic to the cell and raises the possibility that DUX4 triggers coexpression of multitude of DUX4 target and responsive TFs that serve as mediators of FSHD. These TFs may coordinately regulate a network of genes resulting in sustainable activation of the cytotoxic program that leads to pathogenesis. If this is the case, therapeutics targeting DUX4 or DUX4 expression may limit progression of FSHD to new tissue but may not stop muscle wasting in already disease-activated tissue.
Our time-course pooled RNA-seq and single cell/nucleus RNA-seq of primary control and FSHD2 myoblasts and myotubes revealed distinct dynamics of FSHD-specific gene expression during differentiation and demonstrated that all the patient cells exhibit disease-specific gene expression changes even in those with no detectable DUX4 as well as very low FSHD-induced genes expression. We provided direct evidence that DUX4 transcript expression even in a single nucleus can trigger a high expression of downstream target genes in the same myotube, but the expression pattern of downstream genes can vary between nuclei. Specific analysis of nuclei with detectable DUX4 and/or FSHD-induced genes expression revealed co-upregulation of a specific set of transcription factors that may together contribute to the development of the FSHD phenotype.
Methods
Human myoblast culture and differentiation
Human control and FSHD2 myoblast cells from patient quadricep and tibia biopsies, and KD3 immortalized cells from abdominal muscles, were grown on dishes coated with collagen in high glucose DMEM (Gibco) supplemented with 20% FBS (Omega Scientific, Inc.), 1% Pen-Strep (Gibco), and 2% Ultrasor G (Crescent Chemical Co.) [21] . Upon reaching 80% confluence, differentiation was induced by using high glucose DMEM medium supplemented with 2% FBS and ITS supplement (insulin 0.1%, 0.000067% sodium selenite, 0.055% transferrin; Invitrogen). Fresh differentiation medium was changed every 24hrs.
Pooled, single-nucleus and single-cell RNA-seq library preparation and sequencing For pooled RNA-seq for the time-course, total RNA was extracted by using the RNeasy kit (QIAGEN). Between 19 and 38 ng of RNA were converted to cDNA using the SmartSeq 2 protocol [53] . Libraries were constructed with the Nextera DNASample Preparation Kit (Illumina). Single-cell and single-nucleus RNA-seq were performed according to [21] with the following modifications. Myotube single nuclei were isolated from mononucleated cells (MNCs) by washing a 6 cm dish once with trypsin, then adding trypsin for about 5 min until myotubes lifted off the plate and MNCs were still attached. Cells were initially pelleted at 2000 rpm for 2 min and resuspended in lysis buffer with 0.02% IGEPAL CA-630. Lysis was done for 3 minutes, filtered and spun at 4000 rpm for 1 minute. Nuclei were captured on medium IFCs (10-17 um) at a density between 340 and 640 nuclei/ul in a volume of 10 ul. Visual confirmation was aided with the LIVE/DEAD kit (Thermo Fisher Scientific), and cDNA was normalized to approximately 0.1 ng/ul for tagmentation and library prep. Libraries were quality-controlled prior to sequencing based on Agilent 2100 Bioanalyzer profiles and normalized using the KAPA Library Quantification Kit (Illumina). Libraries were sequenced on the Illumina NextSeq500 platform using paired-end 43bp mode with 15 million reads per sample for pooled libraries and paired-end 75bp mode with 1-3 million reads per sample for single-cell and single-nucleus libraries.
RNA FISH (Fluorescent in situ hybridization targeting ribonucleic acid molecules)
FSHD2-19 myoblasts were seeded in micro-slide eight-well plates at ~8x10 4 cells per well, and differentiation was initiated ~20hrs later. After 3 days of differentiation, cells were fixed with 10% neutral buffered formalin at room temperature for 30 min, and the RNA FISH experiments were performed using the RNAscope fluorescent Multiplex system (Advanced Cell Diagnostic Inc.) according to the manufacturer's instructions. Probe-Hs-DUX4-C1, Probe-Hs-LEUTX-C2, and Probe-Hs-SLC34A2-C3 were used. Images were acquired using a Zeiss LSM 510 META confocal microscope.
RNA-seq data processing
Raw reads from both pooled RNA-seq and single-cell and single-nucleus RNA-seq were mapped to hg38 by STAR (version 2.5.1b) [54] using defaults except with a maximum of 10 mismatches per pair, a ratio of mismatches to read length of 0.07, and a maximum of 10 multiple alignments. Quantitation was performed using RSEM (version 1.2.31) [55] by defaults with gene annotations from GENCODE v28, and results were output in transcripts per million (TPM). Myoblast cells were kept for downstream analysis if desmin expression was >=1 TPM, MYOG <1 TPM, number of expressed genes was more than 500 and expression level of GAPDH was higher than 100 TPM. Myotube nuclei were kept for downstream analysis if MYOG expression was >=1 TPM, number of expressed genes was more than 500 and expression level of GAPDH was higher than 100 TPM. We only kept cells and nuclei with a uniquely mapped efficiency higher than 45%. For differential gene expression analysis in differentiation time-course, protein coding and long non-coding RNA genes with at least 5 TPM in both replicates in at least one timepoint and with at least 1 TPM for both reps for both cell lines of the same disease and day were kept. Genes were TMM normalized using edgeR (version 3.18.1) [56] and log2-transformed for downstream analysis. Differential expression analysis per day during differentiation was done by using edgeR with FDR < 0.05. Clustering of differentially expressed genes across the time-course was done by using maSigPro [26] . For dimensionality reduction analysis in single-cell and single-nucleus RNA-seq data, incremental PCA analysis was performed by the IncrementalPCA function from scikit-learn [57] , python 2. t-SNE analysis was performed by using Seurat [58] . Monocle (version 2.4.0) [27] was used to determine the pseudotime trajectory. Gene ontology analysis was done by using Metascape [59] with FDR<0.05. Gene coexpression networks were plotted by using Cytoscape [60] .
Data availability
All pooled-, single cell, and single nucleus RNA-seq data along with their associated meta data will be deposited in the GEO database. [20] and to 552 genes upregulated in DUX4 expressing myotubes over non-expressing mytoubes [22] . Table S1 . Principal components and distributed weights for 10,767 genes in Figure 1B . Table S2 . Gene expression level of 103 genes that are differentially expressed between FSHD2 and control during myoblast differentiation. Table S3 . Gene ontology terms and enriched genes for the 4 clusters in Figures 2 and S4. 
